![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARHGAP30 |
Gene summary for ARHGAP30 |
![]() |
Gene information | Species | Human | Gene symbol | ARHGAP30 | Gene ID | 257106 |
Gene name | Rho GTPase activating protein 30 | |
Gene Alias | ARHGAP30 | |
Cytomap | 1q23.3 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q7Z6I6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
257106 | ARHGAP30 | C21 | Human | Oral cavity | OSCC | 7.83e-05 | 1.75e-01 | 0.2678 |
257106 | ARHGAP30 | C38 | Human | Oral cavity | OSCC | 7.06e-07 | 6.15e-01 | 0.172 |
257106 | ARHGAP30 | C46 | Human | Oral cavity | OSCC | 1.78e-04 | 1.60e-01 | 0.1673 |
257106 | ARHGAP30 | C57 | Human | Oral cavity | OSCC | 1.43e-12 | 2.87e-01 | 0.1679 |
257106 | ARHGAP30 | C06 | Human | Oral cavity | OSCC | 1.76e-03 | 5.21e-01 | 0.2699 |
257106 | ARHGAP30 | LN46 | Human | Oral cavity | OSCC | 2.08e-04 | 1.20e-01 | 0.1666 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARHGAP30 | SNV | Missense_Mutation | c.574G>T | p.Ala192Ser | p.A192S | Q7Z6I6 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ARHGAP30 | SNV | Missense_Mutation | c.1825N>G | p.Phe609Val | p.F609V | Q7Z6I6 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARHGAP30 | SNV | Missense_Mutation | novel | c.2154N>T | p.Glu718Asp | p.E718D | Q7Z6I6 | protein_coding | deleterious_low_confidence(0.01) | benign(0.006) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ARHGAP30 | SNV | Missense_Mutation | c.1384N>A | p.Pro462Thr | p.P462T | Q7Z6I6 | protein_coding | deleterious_low_confidence(0) | benign(0.31) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARHGAP30 | SNV | Missense_Mutation | rs376108588 | c.2948G>A | p.Arg983Gln | p.R983Q | Q7Z6I6 | protein_coding | tolerated(0.11) | probably_damaging(0.988) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARHGAP30 | SNV | Missense_Mutation | c.1891G>A | p.Gly631Arg | p.G631R | Q7Z6I6 | protein_coding | deleterious_low_confidence(0.02) | benign(0.34) | TCGA-D1-A17T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARHGAP30 | SNV | Missense_Mutation | novel | c.1609G>A | p.Ala537Thr | p.A537T | Q7Z6I6 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ARHGAP30 | SNV | Missense_Mutation | novel | c.2188N>A | p.Glu730Lys | p.E730K | Q7Z6I6 | protein_coding | tolerated_low_confidence(0.11) | benign(0.005) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ARHGAP30 | SNV | Missense_Mutation | novel | c.1929N>T | p.Gln643His | p.Q643H | Q7Z6I6 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ARHGAP30 | SNV | Missense_Mutation | novel | c.2501N>C | p.Val834Ala | p.V834A | Q7Z6I6 | protein_coding | tolerated_low_confidence(0.07) | benign(0) | TCGA-E6-A2P8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |